George Clement Dobbins

George Clement Dobbins

Auto-generated profile, based on publicly available information

George Clement Dobbins

Department of Pediatrics, The University of Alabama School of Medicine, CHB 116, 1600 6th Avenue South, Birmingham, AL, USA.

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2008 in Molecular Brain
Verified
Journal Article
Open access
PDF file
GDG Clement Dobbins
G Clement Dobbins
SLShiwen Luo
Shiwen Luo
ZYZhihua Yang
Zhihua Yang
WXWen-Cheng Xiong
Wen-Cheng Xiong
LMLin Mei
Lin Mei
AChR is concentrated at the postjunctional membrane at the neuromuscular junction. However, the underlying mechanism is unclear. We show that α-actinin, a protein known to cross-link F-actin, interacts with rapsyn, a scaffold protein essential for neuromuscular junction formation. α-Actinin, rapsyn, and surface AChR form a ternary complex. Moreover, the rapsyn-α-actinin interaction is increased by agrin, a factor known to stimulate AChR clustering. Downregulation of α-actinin expression inhibits agrin-mediated AChR clustering. Furthermore, the rapsyn-α-actinin interaction can be disrupted by inhibiting Abl and by cholinergic stimulation. Together these results indicate a role for α-actinin in AChR clustering.

10 December 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
GDG. Clement Dobbins
G. Clement Dobbins
APAmit Patki
Amit Patki
DCDongquan Chen
Dongquan Chen
HTHemant K. Tiwari
Hemant K. Tiwari
CHCurtis Hendrickson
Curtis Hendrickson
SRShannon A. Ross
Shannon A. Ross
Background: Congenital cytomegalovirus (cCMV) infection is the most common congenital infection and a leading cause of long-term neurological and sensory sequelae, the most common being sensorineural hearing loss (SNHL). Despite extensive research, clinical or laboratory markers to identify CMV infected children with increased risk for disease have not been identified. This study utilizes viral whole-genome next generation-sequencing (NGS) of specimens from congenitally infected infants to explore viral diversity and specific viral variants that may be associated with symptomatic infection and SNHL. Methods: CMV DNA from urine specimens of 30 infants (17 asymptomatic, 13 symptomatic) was target enriched and next generation sequenced resulting in 93% coverage of the CMV genome allowing analysis of viral diversity. Results: Variant frequency distribution was compared between children with symptomatic and asymptomatic cCMV and those with (n = 13) and without (n = 17) hearing loss. The CMV genes UL48A, UL88, US19 and US22 were found to have an increase in nucleotide diversity in symptomatic children; while UL57, UL20, UL104, US14, UL115, and UL35 had an increase in diversity in children with hearing loss. An analysis of single variant differences between symptomatic and asymptomatic children found UL55 to have the highest number, while the most variants associated with SNHL were in the RL11 gene family. In asymptomatic infants with SNHL, mutations were observed more frequently in UL33 and UL20. Conclusion: CMV genomes from infected newborns can be mapped to 93% of the genome at a depth allowing accurate and reproducible analysis of polymorphisms for variant and gene discovery that may be linked to symptomatic and hearing loss outcomes.

Verified
Journal Article
Open access
PDF file
JSJuliana Sitta
Juliana Sitta
FCFLAVIA DE CARLO
FLAVIA DE CARLO
IKImani Aliah Kirven
Imani Aliah Kirven
JTJohn Hollis Tackett
John Hollis Tackett
PPPatrice Penfornis
Patrice Penfornis
Pier Paolo ClaudioPier Paolo Claudio
Pier Paolo Claudio
Oncolytic virotherapy has shown great promise in mediating targeted tumor destruction through tumor-selective replication and induction of anti-tumor immunity; however, obstacles remain for virus candidates to reach the clinic. These include avoiding neutralizing antibodies, preventing stimulation of the adaptive immune response during intravenous administration, and inducing sufficient apoptosis and immune activation so that the body’s defense can work to eradicate systemic disease. We have developed a co-formulation of oncolytic viruses (OVs) with Imagent® lipid-encapsulated, perfluorocarbon microbubbles (MBs) to protect the OVs from the innate and adaptive immune system. Once inside the MB, the viral particles become acoustically active such that external ultrasound can target the delivery of the virus locally within the tumor. Humanized NSG female mice (Hu-CD34+ NSG-SGM3) engrafted in their flanks with MDA-MB-231-Luc triple-negative breast cancer (TNBC) cells were transduced with MB/OVs, with or without adjuvant Pembrolizumab treatment, and tumor sizes and tumor necrosis were assessed. The presence of CD8+ (cytotoxic T-cells), CD4+ (helper T-cells), and CD25+ (Tregs) tumor-infiltrating lymphocytes (TILs) was quantified in the tumor samples by immunohistochemistry. In an in vivo model of humanized mice engrafted with a human immune system, we observed significantly greater tumor necrosis and smaller tumor mass in human TNBC xenografts systemically treated with MB/OV complexes in the presence or absence of pembrolizumab adjuvant treatment, compared to controls. Additionally, we observed a low ratio of CD4+/CD8+ TILs and a high ratio of CD8+/CD25+ TILs in the MDA-MB-231 xenografts treated with MB/OVs complexes with or without pembrolizumab adjuvant treatment, compared to controls. Our study demonstrated the feasibility of using MBs to target OVs to TNBC through diagnostic ultrasound, which decreased tumor mass by increasing tumor necrosis and stimulated a local and systemic antitumoral immune response by increasing intratumoral CD8+ T-cytotoxic lymphocyte infiltration and decreasing CD25+ Treg cells.

21 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GDG. Clement Dobbins
G. Clement Dobbins
HUHideyo Ugai
Hideyo Ugai
DCDavid T. Curiel
David T. Curiel
GGG. Yancey Gillespie
G. Yancey Gillespie
Studies have demonstrated that oncolytic adenoviruses based on a 24 base pair deletion in the viral E1A gene (D24) may be promising therapeutics for treating a number of cancer types. In order to increase the therapeutic potential of these oncolytic viruses, a novel conditionally replicating adenovirus targeting multiple receptors upregulated on tumors was generated by incorporating an Ad5/3 fiber with a carboxyl terminus RGD ligand. The virus displayed full cytopathic effect in all tumor lines assayed at low titers with improved cytotoxicity over Ad5-RGD D24, Ad5/3 D24 and an HSV oncolytic virus. The virus was then engineered to deliver immunotherapeutic agents such as GM-CSF while maintaining enhanced heterogenic oncolysis.

30 April 2022 in Antiviral Research
Verified
Journal Article
Closed access
GDG. Clement Dobbins
G. Clement Dobbins
DKDavid W. Kimberlin
David W. Kimberlin
SRShannon A. Ross
Shannon A. Ross

10 February 2020 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
GDG. Clement Dobbins
G. Clement Dobbins
APAmit Patki
Amit Patki
DCDongquan Chen
Dongquan Chen
HTHemant K. Tiwari
Hemant K. Tiwari
CHCurtis Hendrickson
Curtis Hendrickson
SRShannon A. Ross
Shannon A. Ross
After publication of the original article [1], we were notified that Fig. 3 has “Fig. 1” posted on the top of it and Figs. 4 and 5 have “Genomic Position” in a different spot.